Skip to main content
Top
Published in: Archives of Virology 10/2015

01-10-2015 | Original Article

Characterization of C69R variant HBsAg: effect on binding to anti-HBs and the structure of virus-like particles

Authors: Nadia Hadiji-Abbes, Wafa Mihoubi, Marta Martin, Carole Karakasyan-Dia, Fakher Frikha, Csilla Gergely, Thierry Jouenne, Ali Gargouri, Raja Mokdad-Gargouri

Published in: Archives of Virology | Issue 10/2015

Login to get access

Abstract

Several variants of the major “a” determinant of the HBsAg, the main target of HBV neutralization by antibodies, have been described. However, mutations outside this region have not been as thoroughly investigated. During the genotyping of HBV from Tunisian patients with chronic hepatitis B, we identified a variant with a C69R substitution in the cytosolic loop of the S protein, resulting in a change in the hydrophobicity profile compared to the wild-type HBsAg. Wild-type and mutant HBsAgs were produced in Saccharomyces cerevisiae and recombinant proteins were tested for their ability to correctly self-assemble into virus-like particles (VLPs), and their ability to bind to HBs antibodies. The C69R substitution resulted in a decrease in binding to commercial anti-HBs antibodies, and although the variant appeared to assemble properly into VLPs, the average size of the particles was larger than that of the wild-type HBsAg. Prediction of the tertiary structure of the C69R mutant revealed a change in the first (aa 60-70) and the second loop (aa 110 to 120) compared to the wild-type protein. Furthermore, we showed by an isothermal titration calorimetry assay that the interaction between the wild-type HBsAg and the anti-HBs antibody was exothermic, whereas that with the mutant C69R was endothermic, indicating an effect on the binding affinity.
Literature
1.
go back to reference Lavanchy D (2004) Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepatitis 11:97–107CrossRef Lavanchy D (2004) Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepatitis 11:97–107CrossRef
2.
go back to reference Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP (2006) Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 28:112–125CrossRefPubMed Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP (2006) Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 28:112–125CrossRefPubMed
3.
go back to reference Michel ML, Tiollais P (1987) Structure and expression of the hepatitis B virus genome. Hepatology 7:615–635CrossRef Michel ML, Tiollais P (1987) Structure and expression of the hepatitis B virus genome. Hepatology 7:615–635CrossRef
4.
go back to reference Zuckerman JN, Zuckerman AJ (2003) Mutations of the surface protein of hepatitis B virus. Antiviral Res 60:75–78CrossRefPubMed Zuckerman JN, Zuckerman AJ (2003) Mutations of the surface protein of hepatitis B virus. Antiviral Res 60:75–78CrossRefPubMed
6.
go back to reference Zhang M, Ge G, Yang Y, Cai X, Fu Q, Cai J, Huang Z (2013) Decreased antigenicity profiles of immune-escaped and drug-resistant hepatitis B surface antigen (HBsAg) double mutants. Virol J 1:292–301CrossRef Zhang M, Ge G, Yang Y, Cai X, Fu Q, Cai J, Huang Z (2013) Decreased antigenicity profiles of immune-escaped and drug-resistant hepatitis B surface antigen (HBsAg) double mutants. Virol J 1:292–301CrossRef
7.
go back to reference Lu HY, Zeng Z, Xu XY, Zhang NL, Yu M, Gong WB (2006) Mutation in surface and polymerase gene of chronic hepatitis B patients with coexisting HBsAg and anti-HBs. World J Gastroenterol 12:4219–4223PubMedCentralPubMed Lu HY, Zeng Z, Xu XY, Zhang NL, Yu M, Gong WB (2006) Mutation in surface and polymerase gene of chronic hepatitis B patients with coexisting HBsAg and anti-HBs. World J Gastroenterol 12:4219–4223PubMedCentralPubMed
8.
go back to reference Seddigh-Tonekaboni S, Waters JA, Jeffers S, Gehrke R, Ofenloch B, Horsch A (2000) Effect of variation in the common “a” determinant on the antigenicity of hepatitis B surface antigen. J Med Virol 60:113–121CrossRefPubMed Seddigh-Tonekaboni S, Waters JA, Jeffers S, Gehrke R, Ofenloch B, Horsch A (2000) Effect of variation in the common “a” determinant on the antigenicity of hepatitis B surface antigen. J Med Virol 60:113–121CrossRefPubMed
9.
go back to reference Verheyen J, Neumann-Fraune M, Berg T, Kaiser R, Obermeier M (2012) The detection of HBsAg mutants expressed in vitro using two different quantitative HBsAg assays. J Clin Virol 54:279–281CrossRefPubMed Verheyen J, Neumann-Fraune M, Berg T, Kaiser R, Obermeier M (2012) The detection of HBsAg mutants expressed in vitro using two different quantitative HBsAg assays. J Clin Virol 54:279–281CrossRefPubMed
10.
go back to reference Szmaragd C, Foster GR, Manica A, Bartholomeusz A, Nichols RA, Balloux F (2006) Genome-wide characterisation of hepatitis B mutations involved in clinical outcome. Heredity 97:389–397CrossRefPubMed Szmaragd C, Foster GR, Manica A, Bartholomeusz A, Nichols RA, Balloux F (2006) Genome-wide characterisation of hepatitis B mutations involved in clinical outcome. Heredity 97:389–397CrossRefPubMed
11.
go back to reference Kfoury-Baz EM (2001) Characterization of a novel hepatitis B virus mutant: demonstration of mutation-induced hepatitis B virus surface antigen group specific `a’ determinant conformation change and its application in diagnostic assays. Transf Med 11:355–362CrossRef Kfoury-Baz EM (2001) Characterization of a novel hepatitis B virus mutant: demonstration of mutation-induced hepatitis B virus surface antigen group specific `a’ determinant conformation change and its application in diagnostic assays. Transf Med 11:355–362CrossRef
12.
go back to reference Jolivet-Reynaud C, Lésenéchal M, O’Donnell B, Becquart L, Foussadier A, Forge F (2001) Localization of hepatitis B surface antigen epitopes present on variants and specifically recognised by anti-hepatitis B surface antigen monoclonal antibodies. J Med Virol 65:241–249CrossRefPubMed Jolivet-Reynaud C, Lésenéchal M, O’Donnell B, Becquart L, Foussadier A, Forge F (2001) Localization of hepatitis B surface antigen epitopes present on variants and specifically recognised by anti-hepatitis B surface antigen monoclonal antibodies. J Med Virol 65:241–249CrossRefPubMed
13.
go back to reference Ly TD (2006) Sensitivities of four new commercial hepatitis B virus surface antigen (HBsAg) assays in detection of HBsAg mutant forms. J Clin Microbiol 44:2321–2326PubMedCentralCrossRefPubMed Ly TD (2006) Sensitivities of four new commercial hepatitis B virus surface antigen (HBsAg) assays in detection of HBsAg mutant forms. J Clin Microbiol 44:2321–2326PubMedCentralCrossRefPubMed
14.
go back to reference Borchani-Chabchoub I, Gargouri A, Mokdad-Gargouri R (2000) Genotyping of Tunisian hepatitis B virus isolates based on the sequencing of preS2 and S regions. Microbes Infect 6:607–612CrossRef Borchani-Chabchoub I, Gargouri A, Mokdad-Gargouri R (2000) Genotyping of Tunisian hepatitis B virus isolates based on the sequencing of preS2 and S regions. Microbes Infect 6:607–612CrossRef
15.
go back to reference Cheong WS, Hyakumura M, Yuen L, Warner N, Locarnini S, Netter HJ (2012) Modulation of the immunogenicity of virus-like particles composed of mutant hepatitis B virus envelope subunits. Antiviral Res 93:209–218CrossRefPubMed Cheong WS, Hyakumura M, Yuen L, Warner N, Locarnini S, Netter HJ (2012) Modulation of the immunogenicity of virus-like particles composed of mutant hepatitis B virus envelope subunits. Antiviral Res 93:209–218CrossRefPubMed
16.
go back to reference Itoh Y, Fujisawa Y (1986) Synthesis in yeast of hepatitis B virus surface Ag modified P31 particles by gene modification. Biochem Biophys Res Commun 141:942–949CrossRefPubMed Itoh Y, Fujisawa Y (1986) Synthesis in yeast of hepatitis B virus surface Ag modified P31 particles by gene modification. Biochem Biophys Res Commun 141:942–949CrossRefPubMed
17.
go back to reference Hadiji-Abbes N, Martin M, Benzina W, Karray-Hakim H, Gergely C, Gargouri A, Mokdad-Gargouri R (2013) Extraction and purification of hepatitis B virus-like M particles from a recombinant Saccharomyces cerevisiae strain using alumina powder. J Virol Methods 87:132–137CrossRef Hadiji-Abbes N, Martin M, Benzina W, Karray-Hakim H, Gergely C, Gargouri A, Mokdad-Gargouri R (2013) Extraction and purification of hepatitis B virus-like M particles from a recombinant Saccharomyces cerevisiae strain using alumina powder. J Virol Methods 87:132–137CrossRef
19.
go back to reference Guex N, Peitsch MC (1997) SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modelling. Electrophoresis 18:2714–2723CrossRefPubMed Guex N, Peitsch MC (1997) SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modelling. Electrophoresis 18:2714–2723CrossRefPubMed
20.
go back to reference Mathet VL, Feld M, Espínola L, Sánchez DO, Ruiz V, Mandó O (2003) Hepatitis B virus S gene mutants in a patient with chronic active hepatitis with circulating Anti-HBs antibodies. J Med Virol 6:18–26CrossRef Mathet VL, Feld M, Espínola L, Sánchez DO, Ruiz V, Mandó O (2003) Hepatitis B virus S gene mutants in a patient with chronic active hepatitis with circulating Anti-HBs antibodies. J Med Virol 6:18–26CrossRef
21.
go back to reference Cuestas ML, Mathet VL, Ruiz V, Minassian ML, Rivero C, Sala A (2006) Unusual naturally occurring humoral and cellular mutated epitopes of hepatitis B virus in a chronically infected Argentine patient with Anti-HBs antibodies. J Clin Microbiol 44:2191–2198PubMedCentralCrossRefPubMed Cuestas ML, Mathet VL, Ruiz V, Minassian ML, Rivero C, Sala A (2006) Unusual naturally occurring humoral and cellular mutated epitopes of hepatitis B virus in a chronically infected Argentine patient with Anti-HBs antibodies. J Clin Microbiol 44:2191–2198PubMedCentralCrossRefPubMed
22.
go back to reference Mangold CM, Streeck RE (1993) Mutational analysis of the cysteine residues in the hepatitis B virus small envelope protein. J Virol 67:4588–4597PubMedCentralPubMed Mangold CM, Streeck RE (1993) Mutational analysis of the cysteine residues in the hepatitis B virus small envelope protein. J Virol 67:4588–4597PubMedCentralPubMed
23.
go back to reference Mangold CM, Unckell F, Werr M, Streeck RE (1995) Secretion and Antigenicity of Hepatitis B Virus Small Envelope Proteins Lacking Cysteines in the Major Antigenic Region. Virology 211:535–543CrossRefPubMed Mangold CM, Unckell F, Werr M, Streeck RE (1995) Secretion and Antigenicity of Hepatitis B Virus Small Envelope Proteins Lacking Cysteines in the Major Antigenic Region. Virology 211:535–543CrossRefPubMed
25.
go back to reference Tian Y, Xu Y, Zhang Z, Meng Z, Qin L, Lu M, Yang D (2007) The amino acid residues at positions 120 to 123 are crucial for the antigenicity of hepatitis B surface antigen. J Clin Microbiol 45:2971–2978PubMedCentralCrossRefPubMed Tian Y, Xu Y, Zhang Z, Meng Z, Qin L, Lu M, Yang D (2007) The amino acid residues at positions 120 to 123 are crucial for the antigenicity of hepatitis B surface antigen. J Clin Microbiol 45:2971–2978PubMedCentralCrossRefPubMed
26.
go back to reference Ma Q, Wang Y (2012) Comprehensive analysis of the prevalence of hepatitis B virus escape mutations in the major hydrophilic region of surface antigen. J Med Virol 84:198–206CrossRefPubMed Ma Q, Wang Y (2012) Comprehensive analysis of the prevalence of hepatitis B virus escape mutations in the major hydrophilic region of surface antigen. J Med Virol 84:198–206CrossRefPubMed
27.
go back to reference Carman WF (1997) The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat 4:11–20CrossRefPubMed Carman WF (1997) The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat 4:11–20CrossRefPubMed
28.
go back to reference Weber B (2006) Diagnostic impact of the genetic variability of the hepatitis B virus surface antigen. J Med Virol 78:59–65CrossRef Weber B (2006) Diagnostic impact of the genetic variability of the hepatitis B virus surface antigen. J Med Virol 78:59–65CrossRef
29.
go back to reference Ren F, Tsubota A, Hirokawa T, Kumada H, Yang Z, Tanaka H (2006) A unique amino acid substitution, T126I, in human genotype C of hepatitis B virus S gene and its possible influence on antigenic structural change. Gene 383:43–51CrossRefPubMed Ren F, Tsubota A, Hirokawa T, Kumada H, Yang Z, Tanaka H (2006) A unique amino acid substitution, T126I, in human genotype C of hepatitis B virus S gene and its possible influence on antigenic structural change. Gene 383:43–51CrossRefPubMed
30.
go back to reference Allen ML, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL (1998) Identification and characterisation of mutations in hepatitis B virus resistant to lamivudine. Hepatology 2:1670–1677CrossRef Allen ML, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL (1998) Identification and characterisation of mutations in hepatitis B virus resistant to lamivudine. Hepatology 2:1670–1677CrossRef
31.
go back to reference Hunt M, McGill JM, Allen MI, Condreay LD (2000) Clinical relevance of hepatitis B viral mutations. Hepatology 31:1037–1044CrossRefPubMed Hunt M, McGill JM, Allen MI, Condreay LD (2000) Clinical relevance of hepatitis B viral mutations. Hepatology 31:1037–1044CrossRefPubMed
32.
go back to reference Wu C, Zhang X, Tian Y, Song J, Yang D, Roggendorf M (2010) Biological significance of amino acid substitutions in hepatitis B surface antigen (HBsAg) for glycosylation, secretion, antigenicity and immunogenicity of HBsAg and hepatitis B virus replication. J Gen Virol 91:483–492CrossRefPubMed Wu C, Zhang X, Tian Y, Song J, Yang D, Roggendorf M (2010) Biological significance of amino acid substitutions in hepatitis B surface antigen (HBsAg) for glycosylation, secretion, antigenicity and immunogenicity of HBsAg and hepatitis B virus replication. J Gen Virol 91:483–492CrossRefPubMed
Metadata
Title
Characterization of C69R variant HBsAg: effect on binding to anti-HBs and the structure of virus-like particles
Authors
Nadia Hadiji-Abbes
Wafa Mihoubi
Marta Martin
Carole Karakasyan-Dia
Fakher Frikha
Csilla Gergely
Thierry Jouenne
Ali Gargouri
Raja Mokdad-Gargouri
Publication date
01-10-2015
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 10/2015
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-015-2515-y

Other articles of this Issue 10/2015

Archives of Virology 10/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine